{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:56:31Z","timestamp":1791168991130,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.addr.2014.10.009","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T19:01:10Z","timestamp":1414004470000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Clinical applications of pulmonary delivery of antibiotics"],"prefix":"10.1016","volume":"85","author":[{"given":"Patrick A.","family":"Flume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"VanDevanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2014.10.009_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.009_bb0010","doi-asserted-by":"crossref","first-page":"118S","DOI":"10.1378\/chest.120.3_suppl.118S","article-title":"Microbiological and immunologic considerations with aerosolized drug delivery","volume":"120","author":"LiPuma","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.009_bb0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0954-6111(05)80348-8","article-title":"The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis","volume":"88","author":"Mukhopadhyay","year":"1994","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0020","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1378\/chest.95.4.822","article-title":"Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients","volume":"95","author":"Laube","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.009_bb0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.009_bb0030","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ppul.20429","article-title":"Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis","volume":"41","author":"Gibson","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.addr.2014.10.009_bb0035","series-title":"2012 Annual Data Report Bethesda, Maryland","article-title":"Cystic Fibrosis Foundation Patient Registry","year":"2013"},{"key":"10.1016\/j.addr.2014.10.009_bb0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ppul.21417","article-title":"The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis","volume":"46","author":"Amin","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0045","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/thx.53.9.732","article-title":"Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"53","author":"Ballmann","year":"1998","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.009_bb0050","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0895-4356(94)00230-N","article-title":"Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection","volume":"48","author":"Demko","year":"1995","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.addr.2014.10.009_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ppul.1950120306","article-title":"Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis","volume":"12","author":"Henry","year":"1992","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0065","first-page":"65","volume":"58","author":"Hoiby","year":"1977","journal-title":"Scand. J. Respir. Dis."},{"key":"10.1016\/j.addr.2014.10.009_bb0070","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009.abs","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1164\/rccm.200710-1599OC","article-title":"Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis","volume":"178","author":"Kozlowska","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ppul.21525","article-title":"Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis","volume":"47","author":"Mayer-Hamblett","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ppul.1950190103","article-title":"Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis","volume":"19","author":"Pamukcu","year":"1995","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0090","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/IAI.67.9.4744-4750.1999","article-title":"Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype","volume":"67","author":"Parad","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.addr.2014.10.009_bb0095","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"Taccetti","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.10.009_bb0100","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2014.10.009_bb0105","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1086\/318075","article-title":"Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis","volume":"183","author":"Burns","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.10.009_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.009_bb0115","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health,","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"Doring","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.009_bb0125","first-page":"173","article-title":"Nebulised therapy and cystic fibrosis","volume":"7","author":"Geddes","year":"1997","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.addr.2014.10.009_bb0130","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(81)90588-2","article-title":"Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"2","author":"Hodson","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.10.009_bb0135","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1183\/09031936.95.08091594","article-title":"Inhalation of antibiotics in cystic fibrosis","volume":"8","author":"Touw","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.10.009_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1569-1993(02)00002-4","article-title":"Inhaled antibiotic therapy: what drug? What dose? What regimen? What formulation?","volume":"1","author":"Smith","year":"2002","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.009_bb0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group,","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0150","doi-asserted-by":"crossref","first-page":"107S","DOI":"10.1378\/chest.120.3_suppl.107S","article-title":"Administration of aerosolized antibiotics in cystic fibrosis patients","volume":"120","author":"Moss","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.009_bb0155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0160","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"J. Infect. Dis"},{"key":"10.1016\/j.addr.2014.10.009_bb0165","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jcf.2012.02.006","article-title":"Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis","volume":"11","author":"Hurley","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.009_bb0170","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1378\/chest.123.5.1495","article-title":"Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis","volume":"123","author":"Smith","year":"2003","journal-title":"Chest"},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.10.009_bb0175","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0954-6111(11)70022-1","article-title":"Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?","volume":"105","author":"Lo","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0180","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.10.009_bb0185","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.009_bb0190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V","article-title":"Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis","volume":"28","author":"Rosenfeld","year":"1999","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0195","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00063198-200311000-00008","article-title":"Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management","volume":"9","author":"Rosenfeld","year":"2003","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0200","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ppul.1121","article-title":"Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization","volume":"32","author":"Munck","year":"2001","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0205","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO;2-1","article-title":"Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974\u20131995)","volume":"28","author":"Frederiksen","year":"1999","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1997","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/1099-0496(200101)31:1<13::AID-PPUL1001>3.0.CO;2-N","article-title":"Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis","volume":"31","author":"Ratjen","year":"2001","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0220","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.009_bb0225","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0230","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.10.009_bb0235","first-page":"43","article-title":"Nebulized gentamicin in children and adolescents with cystic fibrosis","volume":"20","author":"Kun","year":"1984","journal-title":"Aust. Paediatr. J."},{"key":"10.1016\/j.addr.2014.10.009_bb0240","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1469-0691.2011.03627.x","article-title":"Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates","volume":"18","author":"Tramper-Stranders","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2014.10.009_bb0245","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ppul.10019","article-title":"Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study","volume":"33","author":"Heinzl","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jpeds.2005.10.019","article-title":"Cystic fibrosis pulmonary exacerbations","volume":"148","author":"Ferkol","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.10.009_bb0255","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1378\/chest.98.5.1081","article-title":"Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis","volume":"98","author":"Orenstein","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.009_bb0260","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1183\/09031936.01.17407120","article-title":"Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis","volume":"17","author":"Bradley","year":"2001","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.10.009_bb0265","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.009_bb0270","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.10.009_bb0275","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ppul.21311","article-title":"Pulmonary outcome prediction (POP) tools for cystic fibrosis patients","volume":"45","author":"VanDevanter","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0280","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0285","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ppul.21374","article-title":"Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis","volume":"46","author":"Sanders","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0290","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.addr.2014.10.009_bb0295","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1164\/rccm.200202-087OC","article-title":"Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality","volume":"166","author":"Mayer-Hamblett","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0300","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200405-667OC","article-title":"One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis","volume":"171","author":"Ellaffi","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0305","series-title":"Clinical Practice Guidelines for Cystic Fibrosis","article-title":"Treatment of pulmonary exacerbation of cystic fibrosis","author":"Cystic Fibrosis Foundation","year":"1997"},{"key":"10.1016\/j.addr.2014.10.009_bb0310","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ppul.22652","article-title":"Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis","volume":"48","author":"Wagener","year":"2013","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.10.009_bb0315","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0320","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2012.11.007","article-title":"Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring","volume":"12","author":"Stenbit","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.009_bb0325","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/thoraxjnl-2012-202018","article-title":"The new microbiology of cystic fibrosis: it takes a community","volume":"67","author":"LiPuma","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.009_bb0330","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/thorax.57.2.142","article-title":"Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre","volume":"57","author":"Ledson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.009_bb0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"Esther","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.009_bb0340","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jcf.2013.08.011","article-title":"Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial","volume":"13","author":"Tullis","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.10.009_bb0345","series-title":"The, Cochrane database of systematic reviews","first-page":"CD001912","article-title":"Prophylactic antibiotics for cystic fibrosis","author":"Smyth","year":"2003"},{"key":"10.1016\/j.addr.2014.10.009_bb0350","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/adc.70.2.84","article-title":"Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period","volume":"70","author":"Weaver","year":"1994","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.addr.2014.10.009_bb0355","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1067\/mpd.2002.121930","article-title":"Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial","volume":"140","author":"Stutman","year":"2002","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.10.009_bb0360","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","article-title":"Non-cystic fibrosis bronchiectasis","volume":"188","author":"McShane","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0365","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0370","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa","volume":"93","author":"Orriols","year":"1999","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0375","first-page":"1420","article-title":"A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis","volume":"127","author":"Scheinberg","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.10.009_bb0380","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/thx.2008.112284","article-title":"Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa","volume":"65","author":"Dhar","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.10.009_bb0385","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0390","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.10.009_bb0395","series-title":"The, Cochrane database of systematic reviews","first-page":"CD001289","article-title":"Mucolytics for bronchiectasis","author":"Crockett","year":"2001"},{"key":"10.1016\/j.addr.2014.10.009_bb0400","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0405","series-title":"The, Cochrane database of systematic reviews","first-page":"CD001392","article-title":"Prolonged antibiotics for purulent bronchiectasis in children and adults","author":"Evans","year":"2007"},{"key":"10.1016\/j.addr.2014.10.009_bb0410","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0415","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.10.009_bb0420","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM199009203231201","article-title":"Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial","volume":"323","author":"Leoung","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0425","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJM199104183241602","article-title":"A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia","volume":"324","author":"Hirschel","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0430","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society and Infectious Diseases Society of America","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.10.009_bb0435","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2014.10.009_bb0440","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MCC.0b013e328330abcf","article-title":"Aerosolized antibiotics in critically ill ventilated patients","volume":"15","author":"Palmer","year":"2009","journal-title":"Curr. Opin. Crit. Care"},{"key":"10.1016\/j.addr.2014.10.009_bb0445","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/cc5032","article-title":"Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit. Care"},{"key":"10.1016\/j.addr.2014.10.009_bb0450","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2000-9854","article-title":"Aerosol therapy in mechanically ventilated patients: recent advances and new techniques","volume":"21","author":"Fink","year":"2000","journal-title":"Semin. Respir. Crit. Care Med."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14002178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14002178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T13:31:14Z","timestamp":1689600674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X14002178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":90,"alternative-id":["S0169409X14002178"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2014.10.009","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical applications of pulmonary delivery of antibiotics","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2014.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}